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Abstract: Herein we present the first synthesis of bicyclo[1.1.1]pentyl (BCP) sulfoximines from the
corresponding sulfides. Both BCPs and sulfoximines are bioisosteres used in medicinal chemistry and
therefore desirable motifs. The access to BCP sulfides was enabled by the thiol addition to [1.1.1]propellane as
published before. A broad scope with specific limitations was discovered for the sulfoximination. To diversify
the sulfoximines, N-acylations and N-arylations were performed. As the N-arylation was low yielding we
optimized the copper(I) catalyzed reaction. A wide range of aryl iodides could be deployed and competitive
reactions showed that aryl bromides react equally fast. In a scale-up we prepared a suitable precursor for a
BCP drug analogue.
In this work several molecular structures could be determined by single-crystal X-ray diffraction.
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Introduction
Medicinal chemistry constantly demands novel build-
ing blocks and further exploration of chemical space.
The recent focus on saturated hydrocarbons as struc-
tural motifs (‘escape from flatland’)[1] has drawn the
attention of many groups towards bicyclo[1.1.1]pen-
tanes (BCPs).[2] Derived from [1.1.1]propellane (4),
there have been numerous contributions to the syn-
thesis of BCPs with C  C,[3] C  N[4] and C  S[5] bond
formations. The modification of these products is an
emerging field[6] and besides oxidation[5a,7] BCP sul-
fides 5 have not been addressed so far.
Sulfoximines have been described as ‘neglected
opportunity in medicinal chemistry’.[8] With increasing
interest in these bioactive compounds in the last decade
several examples for drug candidates with this polar
sulfur(VI) group have been published (Figure 1).
The development of Roniciclib (1), a promising
pan-CDK inhibitor by Bayer, was unfortunately
stopped in phase II due to a safety signal.[9] In a
diabetes-related SAR study by Amgen compound 2
showed improved in vivo pharmacokinetic properties
and is currently under further investigation.[10] Com-
pound 3 has been disclosed as inhibitor of neutrophil
elastase activity by Boehringer Ingelheim.[11]
Overall, the replacement of other sulfur-based func-
tional groups by sulfoximines can have positive effects
on physicochemical properties and metabolic
stability.[12] Recently, polycyclic sulfoximines gained
interest for their 3D scaffold and easy
diversification.[13]
After early syntheses of sulfoximines from sulf-
oxides with hydrazoic acid,[14] the available methods
underwent significant improvements.[15]
Unprotected sulfoximines can be synthesized from
sulfoxides involving a transition-metal catalyst[16] or
metal-free using ammonium carbamate.[17] The direct
synthesis of sulfoximines from sulfides using the same
ammonium source with diacetoxyiodobenzene as
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oxidant was simultaneously investigated by Bull and
Luisi[18] and Reboul.[19] Sulfoximine syntheses from
sulfilimines and different N-substituted sulfoximines
are summarized in a recent review[20] (Scheme 1). The
modification of sulfoximines 7 at the nitrogen, e. g.
arylations to 8, has also been heavily investigated.[21]
In this work we converted BCP sulfides 5[5a] to
sulfoximines 9. In a scale-up reaction we prepared a
precursor 11f for a BCP-Roniciclib analogue 13.
Further, we investigated the N-arylation of 9 via
copper(I)-catalysis to 10.
Results and Discussion
We started our investigations with literature conditions
for the sulfoximine synthesis by Li et al.
(Scheme 2).[22] With model substrate 5a we obtained a
moderate yield of 55%. In a scale-up (6.81 mmol) with
slightly increased equivalents of oxidant (PhI(OAc)2)
and ammonium source ((NH4)2CO3) the product 5a
could be isolated in 57% yield. With the two-step route
through the sulfoxide (see SI) a similar yield of 62%
(over two steps) was obtained. However, the two-step
route required two purifications by column chromatog-
raphy. Therefore, the reaction from the sulfides 5
seemed advantageous. For the scope we decided to
keep the larger excess of oxidant and ammonium
source of 3.0 and 2.0 equiv., respectively.
A variety of functional groups was tolerated in the
reaction. Alkyl- (9b, c), chloro- (9e, g), trifluorometh-
yl- (9h) and methoxy-benzenes (9d) worked reason-
ably well as long as they were substituted in meta- or
para-position. We found that all ortho-substituted
substrates did not convert to the desired products. The
reason for this might be steric hindrance as the BCP is
already a sterically demanding group. To back-up this
assumption bis-BCP sulfide 5t was also subjected to
the reaction. No corresponding sulfoximine could be
detected.
Figure 1. Sulfoximine-containing drug candidates by Bayer (1), Amgen (2) and Boehringer Ingelheim (3).
Scheme 1. Preliminary work by our group in the synthesis of BCP-sulfides 5 and 6, summary of sulfoximine precursors, N-
arylations of sulfoximines and content of this work.
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The following trend could be observed for the aryl
substituted sulfides. Electron-withdrawing groups like
in 9e, 9g or 9h led to decreased yields, whereas
electron-donating groups like in 9b and 9c increased
the yield compared to 9a. For the methoxy substituted
compound 9d the +M effect outweighs the   I effect.
The sulfur is being oxidized during the reaction which
is favored by a higher electron density.
Purely alkyl substituted sulfides provided the
desired products in generally lower yields. Both BCP-
butyl sulfides (5 j, 5k) are volatile. Therefore, the
substrates were not purified completely after the thiol
addition to 4, but rather used with residual solvent.
With 9 l and 9m the tolerance of alcohols and esters
could also be confirmed.
A double sulfoximination could be performed in a
good yield of 74% to obtain 9n. The sulfide 5o only
led to a low yield of 17%. Presumably, after oxidation/
imination of the first sulfide the electron density in the
benzene ring is lowered which leads to a reduced
reactivity in this reaction (see above). For both
products 9n and 9o we were not able to distinguish or
separate the diastereomers by HPLC. For 9n the meso
diastereomer (R*,S*) could be confirmed by single
crystal X-Ray diffraction (SI).
For the enantioselective synthesis of sulfoximines
we considered a route through enantioselective oxida-
tion to the sulfoxide (S4).[23] However, in all our
attempts with chiral titanium complexes we obtained a
racemic mixture of S4.
As we were interested in building blocks for
medicinal chemistry, we chose to prepare a BCP-
Roniciclib precursor. Therefore, we subjected the 4-
nitrobenzene substituted BCP sulfide 5f to the reaction
in a larger scale (4.52 mmol). The product 9f was
obtained in 45% yield.
The free NH of the sulfoximine group can be
problematic in some reactions. To overcome this issue,
we used a standard N-acylation protocol to protect the
nitrogen (Scheme 3). For the model substrate 9a a
very good yield of 85% was obtained. The BCP-
Roniciclib precursor 11f was obtained in a good yield
(72%) as well. The following steps to 13 were not
included in this study, but should be possible analo-
gous to known Roniciclib syntheses.[24]
For the N-arylation we started our optimization
with model compound 9a and conditions by Bolm
et al. (Table 1).[25] The initial yield was encouraging
with 37% (Entry 1). The variation of the copper(I)
source to different halide salts and more soluble
complexes did not improve the yield of the reaction
(Entries 2–9). Only copper(I) acetate led to an increase
of 2%. The lower cost of copper(I) oxide and the
minor difference in yield made us stick to the latter. A
test reaction with copper(II) was performed and
confirmed that the catalytically active species is copper
(I) (Entry 10). Increasing the catalyst loading from 10
to 20 mol% led to a slightly improved yield of 42%
(Entry 11).
With the designated catalyst, we changed the base
to K2CO3 (Table 2, Entry 1) but obtained a signifi-
cantly lower yield. KOtBu finally increased the yield
Scheme 2. Scope of the sulfoximine synthesis from the BCP-
sulfides 5. Reaction scale: 5, 0.16–0.60 mmol. [a] Reaction
conditions: 2.3 equiv. PhI(OAc)2, 1.5 equiv. (NH4)2CO3.
[b]
Reaction scale: 5a, 6.81 mmol; 5 f, 4.52 mmol. [c] Yield after
two steps from 4. [d] Reaction conditions: 6.0 equiv. PhI(OAc)2,
4.0 equiv. (NH4)2CO3, MeOH (0.05 M).
Scheme 3. N-acylation of BCP-sulfoximines 9 with ethyl
chloroformate. 11f is a suitable precursor for a BCP-Roniciclib
analogue 13.
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to 63% (Entry 2). After different variations in solvents,
temperature and time with no improvement in yield
(Entries 3–9), we stick with the initial conditions with
DMF at 100 °C for 18 h. The addition of 1,2-dimeth-
ylethylenediamine (DMEDA) as a ligand gave a final
boost to an acceptable yield of 70% (Entry 10).
With the optimized conditions for the N-arylation
of BCP sulfoximines 9 we examined the aryl iodide
scope with model compound 9a (Scheme 4). Substitu-
tion in meta-, ortho- and para-position did not disturb
the reaction. The functional group tolerance was very
good, as alkyl- (10b, g, k), methoxy- (10c, h, l),
chloro- (10d, I, m), nitro- (10e) and acyl-groups (10 f,
j) could successfully be retained in this reaction.
Carboxylic esters were not tolerated. Meta-substitu-
tions generally led to the highest yields, close to the
model compound. 3-Iodotoluene even exceeded the
model compound with 75% yield for 10g. Therefore,
this iodide was chosen to react with purely alkyl
substituted BCP sulfoximines to 10p and 10q. With
larger aromatic systems the desired products were
obtained in lower yields (10n, o).
During the scope investigation two different bro-
moiodobenzenes 15a, b were used and in both cases
mixtures of products were obtained (Table 3, En-
tries 1–2). The yield was determined by NMR and
revealed a 1:1.2 and 1:1 ratio of the products,
respectively. This result was supported by mass
spectrometry and the products were confirmed by
HRMS. As the two halides seemed to react equally
fast, 3-bromo-5-chloroiodobenzene (15c) was also
subjected to the reaction. Again, both bromide and
iodide reacted but no product from a reaction of the
chloride could be observed (Entry 3).
In the course of this study we could obtain several
single crystals and determine the structure by X-Ray
diffraction (SI).
Table 1. Screening of different copper catalysts for the N-
arylation of sulfoximine 9a.[a]
Entry Copper salt Yield [%][b]
1 10 mol% Cu2O 37
2 10 mol% CuI 3
3 10 mol% CuBr 15
4 10 mol% CuCl 7
5 10 mol% CuCN 15
6 10 mol% CuOAc 39
7 10 mol% CuTC 1
8 10 mol% CuOTf-toluene 15
9 10 mol% Cu(CH3CN)4PF6 31
10 10 mol% CuO –
11 20 mol% Cu2O 42
[a] Reaction scale: 9a, 0.24 mmol.
[b] Isolated yield.
Table 2. Screening of different bases, solvents and conditions
for the N-arylation of sulfoximine 9a.[a]
Entry Base Solvent Conditions
(temperature, time)
Yield [%][b]
1 K2CO3 DMF 100 °C, 18 h 5
2 KOtBu DMF 100 °C, 18 h 63
3 KOtBu ACN 100 °C, 18 h 31
4 KOtBu DMSO 100 °C, 18 h 48
5 KOtBu toluene 100 °C, 18 h 38
6 KOtBu DMF 120 °C, 18 h 57
7 KOtBu DMF 140 °C, 18 h 54
8 KOtBu DMF 100 °C, 24 h 57
9 KOtBu DMF 100 °C, 48 h 56
10 KOtBu DMF 100 °C, 18 h 70[c]
[a] Reaction scale: 9a, 0.24 mmol.
[b] Isolated yield.
[c] 20 mol% 1,2-dimethylethylenediamine (DEMDA) as addi-
tive.
Scheme 4. Scope of the N-arylation of sulfoximines 9. Reaction
scale: 9, 0.23–0.27 mmol.
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Conclusion
The synthesis of BCP sulfoximines from sulfides
shows great functional group tolerance and can be
used to prepare variable building blocks. The con-
ditions are simple and the reaction can be scaled-up
easily. A limitation can occur with a second sterically
demanding substituent at the sulfide. To diversify the
products N-acylations can be performed as well as
copper(I)-catalyzed N-arylations with aryl halides. The
conditions for the N-arylation were optimized in this
work and a good scope could be shown. For future
applications C2-substituted BCPs would be highly
desirable.[26] The combination with sulfoximines leads
to a great extension of the accessible chemical space.
Experimental Section
Standard Procedure for BCP Sulfoximine Synthe-
sis:
To a stirred solution of sulfide 5a (150 mg, 0.85 mmol) in
MeOH (8.5 mL) were added (NH4)2CO3 (163 mg, 1.70 mmol)
and PhI(OAc)2 (740 mg, 2.55 mmol) at rt. The reaction mixture
was stirred for 30 min (open flask). The solvent was removed
under reduced pressure and the crude product was purified by
column chromatography (cHex/EtOAc 1:1) to give 100 mg
(0.48 mmol, 57% yield) of the desired product 9a as a white
solid.
Standard Procedure for N-arylation of BCP-sulfox-
imines:
An oven-dried vial was charged with a magnetic stir bar, the
sulfoximine 9a (50 mg, 0.24 mmol), Cu2O (6.9 mg, 0.05 mmol)
and KOtBu (54 mg, 0.48 mmol). The vial was evacuated and
backfilled with argon for three times. Then, dry DMF (0.5 mL),
DMEDA (5 μL, 0.05 mmol) and iodobenzene (14a, 40 μL,
74 mg, 0.36 mmol) were added via syringe and the reaction
mixture was stirred at 100 °C for 18 h. After cooling to rt, the
mixture was diluted with CH2Cl2 (5 mL), filtered through a
short silica pad and concentrated under reduced pressure. The
crude product was purified by column chromatography (cHex/
EtOAc 10:1) to give 48 mg (0.17 mmol, 71% yield) of the
desired product 10a as a white solid.
Full experimental details and analytical data (1H NMR, 13C
NMR, X-ray analysis) are provided in the Supporting Informa-
tion (SI).
CCDC 1951387 (9a), 1951388 (9c), 1951389 (9 f), 1951390
(9 i), 1951391 (9n), 1951392 (10a), 1951393 (11a), and
1951394 (11f) contain the supplementary crystallographic data
for this paper. These data can be obtained free of charge from
The Cambridge Crystallographic Data Centre via www.ccdc.
cam.ac.uk/data_request/cif.
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